A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 7, 2015, Pages 826-835

  Scicluna, Brendon P ^a   Klein Klouwenberg, Peter M C ^b,c   Van Vught, Lonneke A ^a   Wiewel, Maryse A ^a   Ong, David S Y ^b,c   Zwinderman, Aeilko H ^d   Franitza, Marek ^b,e   Toliat, Mohammad R ^e   Nürnberg, Peter ^b,e,f   Hoogendijk, Arie J ^a   Horn, Janneke ^b   Cremer, Olaf L ^b   Schultz, Marcus J ^b   Bonten, Marc J ^b,c   Van Der Poll, Tom ^a,g  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department of Intensive Care Medicine ^*  (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d Departments of Clinical Epidemiology and Biostatistics   (Netherlands)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Biomarker; Blood; Microarray; Pneumonia; Sepsis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BIOLOGICAL MARKER; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; ERYTHROMYCIN; INTERLEUKIN 6; INTERLEUKIN 8; OSELTAMIVIR; PROCALCITONIN; APOPTOSIS REGULATORY PROTEIN; CALCITONIN; FAIM PROTEIN, HUMAN; PLAC8 PROTEIN, HUMAN; PROTEIN; PROTEIN PRECURSOR;

ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; BLOOD ANALYSIS; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOMICS; HAEMOPHILUS INFLUENZAE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MORTALITY; PNEUMOCYSTIS JIROVECI; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; BLOOD; COMMUNITY-ACQUIRED INFECTIONS; GENE EXPRESSION PROFILING; GENETICS; MIDDLE AGED; PNEUMONIA; TISSUE MICROARRAY;

AGED; APOPTOSIS REGULATORY PROTEINS; BIOMARKERS; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; PNEUMONIA; PROTEIN PRECURSORS; PROTEINS; TISSUE ARRAY ANALYSIS;

EID: 84943279884     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201502-0355OC     Document Type: Article

References (56)

1. World Health Organization. The top 10 causes of death [updated 2014 May; accessed 2014 Oct 3]. Available from: http://www.who.int/mediacentre/factsheets/fs310/en/index.html
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-1310.
3. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, et al.; PROWESSSHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-2064.
4. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, Niederman MS, Torres A. Severe community-acquired pneumonia: assessment of severity criteria. Am J Respir Crit Care Med 1998;158: 1102-1108.
5. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002;166:717-723.
6. Wunderink RG, Laterre PF, Francois B, Perrotin D, Artigas A, Vidal LO, Lobo SM, Juan JS, Hwang SC, Dugernier T, et al.; CAPTIVATE Trial Group. Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2011;183:1561-1568.
7. Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med 2014;370:543-551.
8. Waterer GW, Kessler LA, Wunderink RG. Delayed administration of antibiotics and atypical presentation in community-acquired pneumonia. Chest 2006;130:11-15.
9. Ferrer R, Martin-Loeches I, Phillips G, Osborn TM, Townsend S, Dellinger RP, Artigas A, Schorr C, Levy MM. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 2014;42:1749-1755.
10. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care 2010; 14:R15.
11. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and metaanalysis. Lancet Infect Dis 2013;13:426-435.
12. Bloos F, Reinhart K. Rapid diagnosis of sepsis. Virulence 2014;5: 154-160.
13. Torres A, Ramirez P, Montull B, Menéndez R. Biomarkers and community-acquired pneumonia: tailoring management with biological data. Semin Respir Crit Care Med 2012;33: 266-271.
14. Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis 2013;26: 159-167.
15. Claus RA, Otto GP, Deigner HP, Bauer M. Approaching clinical reality: markers for monitoring systemic inflammation and sepsis. Curr Mol Med 2010;10:227-235.
16. Skibsted S, Bhasin MK, Aird WC, Shapiro NI. Bench-to-bedside review: future novel diagnostics for sepsis. A systems biology approach. Crit Care 2013;17:231.
17. Kofoed K, Andersen O, Kronborg G, Tvede M, Petersen J, Eugen-Olsen J, Larsen K. Use of plasma C-reactive protein, procalcitonin, neutrophils, macrophage migration inhibitory factor, soluble urokinase-type plasminogen activator receptor, and soluble triggering receptor expressed on myeloid cells-1 in combination to diagnose infections: a prospective study. Crit Care 2007;11:R38.
18. Gibot S, Béné MC, Noel R, Massin F, Guy J, Cravoisy A, Barraud D, De Carvalho Bittencourt M, Quenot JP, Bollaert PE, et al. Combination biomarkers to diagnose sepsis in the critically ill patient. Am J Respir Crit Care Med 2012;186:65-71.
19. Casserly B, Read R, Levy MM. Multimarker panels in sepsis. Crit Care Clin 2011;27:391-405.
20. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. The use of geneexpression profiling to identify candidate genes in human sepsis. Am J Respir Crit Care Med 2007;176:676-684.
21. Johnson SB, Lissauer M, Bochicchio GV, Moore R, Cross AS, Scalea TM. Gene expression profiles differentiate between sterile SIRS and early sepsis. Ann Surg 2007;245:611-621.
22. Jani IV, Peter TF. How point-of-care testing could drive innovation in global health. N Engl J Med 2013;368:2319-2324.
23. Klein Klouwenberg PM, van Mourik MSM, Ong DSY, Horn J, Schultz MJ, Cremer OL, Bonten MJM; MARS Consortium. Electronic implementation of a novel surveillance paradigm for ventilatorassociated events. Feasibility and validation. Am J Respir Crit Care Med 2014;189:947-955.
24. Klein Klouwenberg PM, Ong DSY, Bos LDJ, de Beer FM, van Hooijdonk RTM, Huson MA, Straat M, van Vught LA, Wieske L, Horn J, et al. Interobserver agreement of Centers for Disease Control and Prevention criteria for classifying infections in critically ill patients. Crit Care Med 2013;41:2373-2378.
25. Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The International Sepsis Forum Consensus Conference on definitions of infection in the intensive care unit. Crit Care Med 2005;33:1538-1548.
26. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute Physiology and Chronic Health Evaluation (APACHE) IV: hospital mortality assessment for today's critically ill patients. Crit Care Med 2006;34: 1297-1310.
27. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. pROC: an open-source package for R and S1 to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
28. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med 2014;371:380-383.
29. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med 2013;369:840-851.
30. Scicluna BP, van 't Veer C, Nieuwdorp M, Felsmann K, Wlotzka B, Stroes ES, van der Poll T. Role of tumor necrosis factor-α in the human systemic endotoxin-induced transcriptome. PLoS One 2013; 8:e79051.
31. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, Chen RO, Brownstein BH, Cobb JP, Tschoeke SK, et al.; Inflamm and Host Response to Injury Large Scale Collab. Res. Program. A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032-1037.
32. Chung TP, Laramie JM, Meyer DJ, Downey T, Tam LH, Ding H, Buchman TG, Karl I, Stormo GD, Hotchkiss RS, et al. Molecular diagnostics in sepsis: from bedside to bench. J Am Coll Surg 2006; 203:585-598.
33. Brownstein BH, Logvinenko T, Lederer JA, Cobb JP, Hubbard WJ, Chaudry IH, Remick DG, Baker HV, Xiao W, Mannick JA. Commonality and differences in leukocyte gene expression patterns among three models of inflammation and injury. Physiol Genomics 2006;24:298-309.
34. Prucha M, Ruryk A, Boriss H, Möller E, Zazula R, Herold I, Claus RA, Reinhart KA, Deigner P, Russwurm S. Expression profiling: toward an application in sepsis diagnostics. Shock 2004;22:29-33.
35. Tang BM, McLean AS, Dawes IW, Huang SJ, Lin RC. Gene-expression profiling of peripheral blood mononuclear cells in sepsis. Crit Care Med 2009;37:882-888.
36. Tang BM, McLean AS, Dawes IW, Huang SJ, Cowley MJ, Lin RC. Gene-expression profiling of gram-positive and gram-negative sepsis in critically ill patients. Crit Care Med 2008;36: 1125-1128.
37. Payen D, Lukaszewicz AC, Belikova I, Faivre V, Gelin C, Russwurm S, Launay JM, Sevenet N. Gene profiling in human blood leucocytes during recovery from septic shock. Intensive Care Med 2008;34: 1371-1376.
38. Pachot A, Lepape A, Vey S, Bienvenu J, Mougin B, Monneret G. Systemic transcriptional analysis in survivor and non-survivor septic shock patients: a preliminary study. Immunol Lett 2006;106: 63-71.
39. Cobb JP, Moore EE, Hayden DL, Minei JP, Cuschieri J, Yang J, Li Q, Lin N, Brownstein BH, Hennessy L, et al. Validation of the riboleukogram to detect ventilator-associated pneumonia after severe injury. Ann Surg 2009;250:531-539.
40. Parnell GP, Tang BM, Nalos M, Armstrong NJ, Huang SJ, Booth DR, McLean AS. Identifying key regulatory genes in the whole blood of septic patients to monitor underlying immune dysfunctions. Shock 2013;40:166-174.
41. Lissauer ME, Johnson SB, Bochicchio GV, Feild CJ, Cross AS, Hasday JD, Whiteford CC, Nussbaumer WA, Towns M, Scalea TM. Differential expression of toll-like receptor genes: sepsis compared with sterile inflammation 1 day before sepsis diagnosis. Shock 2009; 31:238-244.
42. Jenner RG, Young RA. Insights into host responses against pathogens from transcriptional profiling. Nat Rev Microbiol 2005;3:281-294.
43. Yu SL, Chen HW, Yang PC, Peck K, Tsai MH, Chen JJW, Lin FY. Differential gene expression in gram-negative and gram-positive sepsis. Am J Respir Crit Care Med 2004;169:1135-1143.
44. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-874.
45. Wu Y, Wang F, Fan X, Bao R, Bo L, Li J, Deng X. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care 2012;16:R229.
46. Póvoa P, Coelho L, Almeida E, Fernandes A, Mealha R, Moreira P, Sabino H. C-reactive protein as a marker of infection in critically ill patients. Clin Microbiol Infect 2005;11:101-108.
47. Lemarié J, Barraud D, Gibot S. Host response biomarkers in sepsis: overview on sTREM-1 detection. Methods Mol Biol 2015;1237: 225-239.
48. Nakamura A, Wada H, Ikejiri M, Hatada T, Sakurai H, Matsushima Y, Nishioka J, Maruyama K, Isaji S, Takeda T, et al. Efficacy of procalcitonin in the early diagnosis of bacterial infections in a critical care unit. Shock 2009;31:586-591.
49. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004;39:206-217.
50. Tang BM, Eslick GD, Craig JC, McLean AS. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 2007;7:210-217.
51. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006; 34:1996-2003.
52. US Department of Health and Human Services. Draft guidance for industry, clinical laboratories, and staff: in vitro diagnostic multivariate index assays [2007; accessed 2014 Oct 3]. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071455.pdf
53. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL, Nadler RB. Evaluation of percentage of free serum prostatespecific antigen to improve specificity of prostate cancer screening. JAMA 1995;274:1214-1220.
54. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-616.
55. van 't Veer LJ, Dai H, van de Vijver MJ, He YDD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
56. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev 2012;9:CD007498.